Novartis Issues $120M Drug Recall, Plant Suspension

Law360, New York (January 9, 2012, 2:08 PM EST) -- Novartis Consumer Health Inc. recalled several popular over-the-counter drugs and suspended operations at a Nebraska facility Sunday following consumer complaints about damaged pills, inconsistent packaging and mixed tablets, taking a $120 million charge to do so.

The drugmaker said it was voluntarily pulling certain lots of Excedrin, NoDoz, Bufferin and Gas-X Prevention over concerns that they may contain broken or chipped pills, or stray tablets or capsules from different Novartis products.

An estimated $120 million charge in the fourth quarter of 2011 will cover the recall...
To view the full article, register now.